BioInvent International (BINV.ST) Stock Price

BioInvent International Price

OMX·CLOSED
22.85SEK-0.20 (-0.87 %)
Market closed

Over the last 19 years BioInvent International grew revenue by 8.2% annually, reaching 226.50 M SEK. For BioInvent International, the net margin of -147.0% is up versus -1,439.1% a few years ago. The consensus 12-month price target for BioInvent International is 91.80 SEK, about 301.8% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.

BioInvent International stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioInvent International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioInvent International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioInvent International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioInvent International Stock Price History
DateBioInvent International Price
7/30/202622.85 SEK
7/29/202623.05 SEK
7/28/202623.40 SEK
7/27/202623.40 SEK
7/24/202622.60 SEK
7/23/202622.10 SEK
7/22/202622.55 SEK
7/21/202622.90 SEK
7/20/202622.65 SEK
7/17/202622.65 SEK
7/15/202622.90 SEK
7/14/202622.65 SEK
7/13/202622.90 SEK
7/10/202623.00 SEK
7/9/202623.25 SEK
7/8/202623.65 SEK
7/7/202624.10 SEK
7/6/202624.80 SEK
7/3/202625.45 SEK
7/2/202625.30 SEK
7/1/202624.40 SEK
6/30/202624.75 SEK
6/29/202624.05 SEK
6/26/202624.15 SEK
6/25/202624.10 SEK
6/24/202623.45 SEK
6/23/202623.70 SEK
6/22/202622.90 SEK
6/18/202623.10 SEK
6/17/202623.50 SEK
6/16/202622.90 SEK
6/15/202623.40 SEK
6/12/202624.20 SEK
6/11/202624.35 SEK
6/10/202626.60 SEK
6/9/202627.00 SEK
6/8/202629.05 SEK
6/5/202630.10 SEK
6/4/202630.70 SEK
6/3/202629.75 SEK
6/2/202629.45 SEK
6/1/202631.10 SEK
5/29/202633.10 SEK
5/28/202633.75 SEK
5/27/202629.85 SEK
5/26/202629.10 SEK
5/25/202628.75 SEK
5/22/202627.50 SEK
5/21/202625.65 SEK
5/20/202625.80 SEK
5/19/202625.50 SEK
5/18/202622.80 SEK
5/15/202623.00 SEK
5/13/202622.05 SEK
5/12/202621.25 SEK
5/11/202623.90 SEK
5/8/202623.10 SEK
5/7/202622.80 SEK
5/6/202622.35 SEK
5/5/202622.10 SEK
5/4/202622.30 SEK
4/30/202621.95 SEK
4/29/202622.40 SEK
4/28/202621.55 SEK
4/27/202622.00 SEK
4/24/202622.05 SEK
4/23/202622.30 SEK
4/22/202622.15 SEK
4/21/202621.90 SEK
4/20/202622.00 SEK
4/17/202622.35 SEK
4/16/202622.70 SEK
4/15/202622.40 SEK
4/14/202623.20 SEK
4/13/202622.95 SEK
4/10/202622.80 SEK
4/9/202622.10 SEK
4/8/202622.45 SEK
4/7/202621.90 SEK
4/2/202623.00 SEK
4/1/202623.55 SEK
3/31/202622.25 SEK
3/30/202621.75 SEK
3/27/202622.30 SEK
3/26/202622.60 SEK
3/25/202623.50 SEK
3/24/202622.15 SEK
3/23/202622.25 SEK
3/20/202621.80 SEK
3/19/202622.60 SEK
3/18/202623.40 SEK
3/17/202622.25 SEK
3/16/202622.15 SEK
3/13/202622.00 SEK
3/12/202623.10 SEK
3/11/202623.20 SEK
3/10/202623.40 SEK
3/9/202622.25 SEK
3/6/202622.70 SEK
3/5/202623.00 SEK
3/4/202622.30 SEK
3/3/202621.60 SEK
3/2/202622.15 SEK
2/27/202623.25 SEK
2/26/202623.30 SEK
2/25/202626.30 SEK
2/24/202626.35 SEK
2/23/202626.40 SEK
2/20/202627.15 SEK
2/19/202626.60 SEK
2/18/202625.75 SEK
2/17/202625.20 SEK
2/16/202626.05 SEK
2/13/202625.95 SEK
2/12/202625.75 SEK
2/11/202626.40 SEK
2/10/202626.90 SEK
2/9/202626.30 SEK
2/6/202626.00 SEK
2/5/202629.00 SEK
2/4/202629.55 SEK
2/3/202629.65 SEK
2/2/202629.65 SEK
1/30/202629.60 SEK
1/29/202630.05 SEK
1/28/202631.10 SEK
1/27/202631.60 SEK
1/26/202631.00 SEK
1/23/202630.70 SEK
1/22/202628.55 SEK
1/21/202628.05 SEK
1/20/202628.45 SEK
1/19/202627.60 SEK
1/16/202629.20 SEK
1/15/202629.95 SEK
1/14/202630.20 SEK
1/13/202630.80 SEK
1/12/202630.55 SEK
1/9/202630.30 SEK
1/8/202631.20 SEK
1/7/202631.45 SEK
1/5/202629.95 SEK
1/2/202629.35 SEK
12/30/202529.40 SEK
12/29/202530.00 SEK
12/23/202529.75 SEK
12/22/202529.60 SEK
12/19/202528.95 SEK
12/18/202528.45 SEK
12/17/202527.80 SEK
12/16/202527.95 SEK
12/15/202528.50 SEK
12/12/202528.40 SEK
12/11/202528.25 SEK
12/10/202528.00 SEK
12/9/202528.65 SEK
12/8/202529.15 SEK
12/5/202528.85 SEK
12/4/202529.05 SEK
12/3/202527.10 SEK
12/2/202527.15 SEK
12/1/202527.50 SEK
11/28/202528.00 SEK
11/27/202528.80 SEK
11/26/202528.60 SEK
11/25/202529.35 SEK
11/24/202530.05 SEK
11/21/202529.30 SEK
11/20/202530.90 SEK
11/19/202531.25 SEK
11/18/202528.95 SEK
11/17/202529.90 SEK
11/14/202530.15 SEK
11/13/202531.20 SEK
11/12/202531.00 SEK
11/11/202531.00 SEK
11/10/202531.30 SEK
11/7/202531.65 SEK
11/6/202531.80 SEK
11/5/202533.35 SEK
11/4/202533.15 SEK
11/3/202533.90 SEK
10/31/202531.85 SEK
10/30/202533.30 SEK
10/29/202531.10 SEK
10/28/202527.30 SEK
10/27/202528.30 SEK
10/24/202527.80 SEK
10/23/202527.40 SEK
10/22/202526.15 SEK
10/21/202526.50 SEK
10/20/202527.00 SEK
10/17/202526.75 SEK
10/16/202528.95 SEK
10/15/202528.35 SEK
10/14/202527.25 SEK
10/13/202527.00 SEK
10/10/202527.40 SEK
10/9/202528.55 SEK
10/8/202529.30 SEK
10/7/202528.10 SEK
10/6/202528.30 SEK
10/3/202528.00 SEK
10/2/202527.05 SEK
10/1/202528.15 SEK
9/30/202528.25 SEK
9/29/202528.15 SEK
9/26/202528.70 SEK
9/25/202529.90 SEK
9/24/202530.00 SEK
9/23/202529.50 SEK
9/22/202529.70 SEK
9/19/202530.65 SEK
9/18/202531.30 SEK
9/17/202530.90 SEK
9/16/202529.65 SEK
9/15/202527.50 SEK
9/12/202529.25 SEK
9/11/202529.50 SEK
9/10/202529.90 SEK
9/9/202529.10 SEK
9/8/202529.40 SEK
9/5/202528.50 SEK
9/4/202528.75 SEK
9/3/202529.85 SEK
9/2/202529.80 SEK
9/1/202531.20 SEK
8/29/202531.05 SEK
8/28/202531.75 SEK
8/27/202532.10 SEK
8/26/202533.25 SEK
8/25/202536.15 SEK
8/22/202537.80 SEK
8/21/202536.85 SEK
8/20/202536.85 SEK
8/19/202537.55 SEK
8/18/202537.00 SEK
8/15/202538.85 SEK
8/14/202537.55 SEK
8/13/202537.25 SEK
8/12/202537.00 SEK
8/11/202538.25 SEK
8/8/202539.70 SEK
8/7/202538.95 SEK
8/6/202538.20 SEK
8/5/202537.65 SEK
8/4/202537.05 SEK
Access this data via the Eulerpool API
Get Free API Key

BioInvent International Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
71.46 M SEK
-369.94 M SEK
-330.30 M SEK
Jan 1, 2024
44.69 M SEK
-471.06 M SEK
-429.38 M SEK
Jan 1, 2025
226.50 M SEK
-351.39 M SEK
-332.86 M SEK
Jan 1, 2026 (e)
166.80 M SEK
-137.72 M SEK
-498.90 M SEK
Jan 1, 2027 (e)
600.05 M SEK
-495.44 M SEK
-65.23 M SEK
Jan 1, 2028 (e)
82.13 M SEK
-67.81 M SEK
-148.08 M SEK
Jan 1, 2029 (e)
40.00 M SEK
-33.03 M SEK
0.00 SEK
Jan 1, 2030 (e)
40.00 M SEK
-33.03 M SEK
0.00 SEK

BioInvent International Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 2, 2026, 4:01 AM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
15.0071.0045.0038.0093.00147.0019.00326.0071.0044.00226.00166.00600.0082.0040.0040.00
-67.39373.33-36.62-15.56144.7458.06-87.071,615.79-78.22-38.03413.64-26.55261.45-86.33-51.22–
93.3398.5993.33100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00
14.0070.0042.0038.0093.00147.0019.00326.0071.0044.00226.00166.00600.0082.0040.0040.00
-94.00-62.00-100.00-123.00-138.00-76.00-278.00-50.00-369.00-471.00-351.00-137.00-495.00-67.00-33.00-33.00
-626.67-87.32-222.22-323.68-148.39-51.70-1,463.16-15.34-519.72-1,070.45-155.31-82.53-82.50-81.71-82.50-82.50
-90.00-62.00-100.00-123.00-139.00-76.00-278.00-34.00-330.00-429.00-332.00-498.00-65.00-148.00––
69.81-31.1161.2923.0013.01-45.32265.79-87.77870.5930.00-22.6150.00-86.95127.69––
7.1211.6512.5015.2121.5932.8854.1664.9765.8065.6665.8765.8765.8765.8765.8765.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioInvent International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioInvent International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioInvent International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioInvent International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioInvent International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioInvent International stock margins

The BioInvent International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioInvent International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioInvent International.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-1,435.16 %
-1,439.13 %
Jan 1, 2022
100.00 %
-15.61 %
-10.45 %
Jan 1, 2023
100.00 %
-517.68 %
-462.22 %
Jan 1, 2024
100.00 %
-1,054.15 %
-960.87 %
Jan 1, 2025
100.00 %
-155.14 %
-146.96 %
Jan 1, 2026 (e)
100.00 %
-82.57 %
-299.11 %
Jan 1, 2027 (e)
100.00 %
-82.57 %
-10.87 %
Jan 1, 2028 (e)
100.00 %
-82.57 %
-180.30 %

BioInvent International Stock Revenue, EBIT, Earnings per Share

The BioInvent International earnings per share therefore indicates how much revenue BioInvent International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.36 SEK
-5.14 SEK
-5.15 SEK
Jan 1, 2022
5.02 SEK
-0.78 SEK
-0.52 SEK
Jan 1, 2023
1.09 SEK
-5.62 SEK
-5.02 SEK
Jan 1, 2024
0.68 SEK
-7.17 SEK
-6.54 SEK
Jan 1, 2025
3.44 SEK
-5.34 SEK
-5.05 SEK
Jan 1, 2026 (e)
2.54 SEK
-2.09 SEK
-7.58 SEK
Jan 1, 2027 (e)
9.12 SEK
-7.52 SEK
-0.99 SEK
Jan 1, 2028 (e)
1.25 SEK
-1.03 SEK
-2.25 SEK

BioInvent International business model & stock analysis

BioInvent International AB is a Swedish biopharmaceutical company specializing in the discovery and development of therapeutic antibodies. It was founded in 1986 and is headquartered in Lund, Sweden. BioInvent conducts research and development activities in the fields of immuno-oncology, inflammatory diseases, and fibrosis.

BioInvent International SWOT Analysis

Strengths

1. Innovative and diverse product portfolio, including antibody-based therapeutics.

2. Strong research and development capabilities, facilitating discovery of novel drug candidates.

3. Robust intellectual property rights, safeguarding inventions and promoting competitiveness.

4. Established collaborations with reputable pharmaceutical companies, enhancing market reach and potential partnerships.

Weaknesses

1. Relatively small scale and limited resources compared to major industry players.

2. Dependency on key clients and partners, which may pose risks to revenue and growth prospects.

3. Potential vulnerability to changes in regulatory environment and reimbursement policies.

4. Limited geographical presence, constraining market opportunities in certain regions.

Opportunities

1. Growing demand for targeted therapies and precision medicine, offering market expansion opportunities.

2. Increasing prevalence of chronic diseases, creating higher demand for effective treatment options.

3. Potential for strategic collaborations and partnerships, enabling access to complementary expertise and resources.

4. Advances in technological capabilities, such as antibody engineering, opening new avenues for innovation.

Threats

1. Intense competition from larger pharmaceutical companies with greater resources and market presence.

2. Uncertainty surrounding regulatory approvals and clinical trial outcomes, impacting product development timelines.

3. Risks associated with potential side effects or adverse events related to newly developed therapeutics.

4. Volatility in global economic conditions and exchange rates, affecting financial stability and investment decisions.

BioInvent International Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioInvent International historical P/E ratio, EBIT multiple, and P/S ratio

BioInvent International annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioInvent International shares outstanding

The number of shares of BioInvent International was 65.87 M in 2025. This indicates how many shares BioInvent International is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
54.16 M Stocks
Jan 1, 2022
64.97 M Stocks
Jan 1, 2023
65.80 M Stocks
Jan 1, 2024
65.66 M Stocks
Jan 1, 2025
65.87 M Stocks
Jan 1, 2026 (e)
65.87 M Stocks
Jan 1, 2027 (e)
65.87 M Stocks
Jan 1, 2028 (e)
65.87 M Stocks

BioInvent International stock splits

In BioInvent International's history, there have been no stock splits.

Current BioInvent International forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
12.50 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
91.80
Last Price
22.95
Currency
SEK
12M Return Potential
300.00 %
LTM Return
0 %

BioInvent International Earnings Calls

2025

BioInvent International Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/23/2023-1.30SEK9.14 MSEK2023 Q2
4/25/2023-1.30SEK8.12 MSEK2023 Q1
2/21/2023-1.28SEK7.10 MSEK2022 Q4
10/27/2022-1.19SEK8.12 MSEK2022 Q3
8/25/2022-1.18SEK-SEK2022 Q2
4/27/2022-1.70SEK-SEK2022 Q1
2/23/2022-1.40SEK54.81 MSEK2021 Q4
10/28/2021-1.74SEK27.40 MSEK2021 Q3
8/26/2021-1.15SEK33.49 MSEK2021 Q2
2/27/2020-2.00SEK16.24 MSEK2019 Q4

EESG©

Eulerpool ESG Scorecard© for the BioInvent International stock

45/100
34
Environment
47
Social
53
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees73
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BioInvent International shareholder structure

% Name
1.97130%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
1.12934%
Lannebo Kapitalförvaltning AB
Lannebo Kapitalförvaltning AB
0.95562%
Healthinvest Partners AB
Healthinvest Partners AB
0.60049%
SEB Investment Management AB
SEB Investment Management AB
0.38646%
Skandia Fonder AB
Skandia Fonder AB
0.12639%
Storebrand Kapitalforvaltning AS
Storebrand Kapitalforvaltning AS

BioInvent International Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.2%
Float Shares
-
Shares Outstanding
-

BioInvent International Executives and Management Board

MW

Dr. Martin Welschof

(64)

Chief Executive Officer

Compensation5.10 M SEK
BF

Mr. Bjoern Frendeus

(52)

Chief Scientific Officer · since 2018

Compensation2.35 M SEK
LK

Mr. Leonard Kruimer

(67)

Independent Chairman of the Board

Compensation782,000.00 SEK
BS

Dr. Bernd Seizinger

(69)

Independent Director

Compensation595,000.00 SEK
HB

Hr. Kristoffer Bissessar

(57)

Independent Director

Compensation520,000.00 SEK

Frequently asked questions about BioInvent International

The business model of BioInvent International AB revolves around the discovery and development of innovative antibody-based immunotherapies. As a biopharmaceutical company, BioInvent focuses on identifying and targeting cancer and immune-mediated inflammatory diseases. Through its strong expertise in antibody research and proprietary antibody library, the company aims to develop novel drug candidates and partner with pharmaceutical companies for further clinical development and commercialization. By leveraging its unique technology platforms, BioInvent strives to provide effective and safe therapies to patients in need, while also generating value for its shareholders and partners.

All fundamentals and in-depth analysis of BioInvent International

Our stock analysis for BioInvent International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioInvent International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioInvent International Stock
BioInvent International Revenue→
BioInvent International Stock
BioInvent International Net Income→
BioInvent International Stock
BioInvent International P/E→
BioInvent International Stock
BioInvent International P/S→
BioInvent International Stock
BioInvent International EBIT→
BioInvent International Stock
BioInvent International Dividend→
BioInvent International Stock
BioInvent International Directors Dealings→
BioInvent International Stock
BioInvent International Stocks→
BioInvent International Stock
BioInvent International Market capitalization→
BioInvent International Stock
BioInvent International Debt→
BioInvent International Stock
BioInvent International Liabilities→
BioInvent International Stock
BioInvent International Equity→
BioInvent International Stock
BioInvent International AAQS→
BioInvent International Stock
BioInvent International Employees→
BioInvent International Stock
BioInvent International ROE→
BioInvent International Stock
BioInvent International ROA→
BioInvent International Stock
BioInvent International ROCE→
BioInvent International Stock
BioInvent International News→
BioInvent International Stock
BioInvent International Analyst Price Targets→

Health Stocks

BioLASCO Taiwan CoBioInfra CoBiolife SciencesBiohit OyjBioLife SolutionsBiohavenBiolight Life SciencesBiogend Therapeutics CoBioLineRxBiogenBioMarin PharmaceuticalBiogaiaAll Stocks A–Z →